Flu shots market reached a value of $9.20 billion in 2025 and is expected to expand to $18.30 billion by 2035, registering a CAGR of 7.2% over the forecast period from 2026 to 2035. The expansion of seasonal influenza vaccination policies and programmes is emerging as a defining trend in the global flu shots market, with wide implications for demand growth and immunization strategy adoption worldwide. Public health authorities, led by the World Health Organization (WHO), are actively encouraging countries to integrate influenza vaccines into national immunization schedules and strengthen coverage among high-risk populations, including older adults, pregnant women, and health workers. As this policy environment evolves, manufacturers and healthcare systems are adjusting production planning and distribution frameworks to meet expanding programme requirements. The increasing integration of influenza vaccination into routine public health practice reinforces the vaccine’s role in reducing disease burden and informs long-term market projections. This trend is particularly evident as global surveillance and policy support intensify around the annual need for updated immunization.
Browse the full report description of “Flu Shots Market Size, Share & Trends Analysis Report by Vaccine Type (Inactivated Influenza Vaccines (IIV), and Recombinant Influenza Vaccines), by Formulation (Trivalent Flu Shots, and Quadrivalent Flu Shots), and by Patient Group (Pediatric, Adult, and Geriatric), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/flu-shots-market
Recent coverage data from the 2024–25 influenza season demonstrate that vaccination uptake remains significant, with 50.2% of US children (aged 6 months to 17 years) receiving at least one dose of flu vaccine, despite declines compared to recent seasons. Concurrent data show coverage variability across age groups, with higher uptake among older populations in the US, and substantial national vaccine supply distribution, exceeding 145 million doses throughout the season. These figures highlight sustained demand for influenza vaccines and the critical role of immunization programmes in shaping annual vaccine utilization and market volume.
Key Findings on Influenza Vaccination Uptake
- National immunization policies are expanding, with WHO guidance reinforcing inclusion of influenza vaccines in routine programmes.
- In the 2024–25 US season, 50.2% of children aged 6 months to 17 years received influenza vaccination.
- Seasonal vaccine supply distribution in the US reached more than 145 million doses during 2024-25.
- Coverage among adults and targeted populations remains central to market demand dynamics.
- Ongoing WHO and partner efforts enhance national programme implementation and coverage evaluation.
- Expanded immunization policies support higher annual demand and reinforce predictable market cycles.
Recent Product and Supply Developments in the Global Flu Shots Market
- In January 2026, Moderna filed regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, with the FDA, EMA, Health Canada, and Australia’s TGA. The candidate is designed for adults aged 50 years and older, reflecting a targeted approach toward higher-risk populations.
- In July 2025, GSK plc initiated distribution of its trivalent seasonal influenza vaccines, FLULAVAL and FLUARIX, to healthcare providers and retail pharmacies across the US for the 2025–26 flu season. The shipments followed FDA licensing and lot-release clearance, with both vaccines supplied as 0.5 mL single-dose prefilled syringes approved for individuals six months of age and above.
- In July 2025, CSL Seqirus, operating under CSL Ltd., began shipping its influenza vaccine portfolio for the 2025–26 flu season in the US. The company emphasized early and timely supply to support seasonal immunization efforts and reduce the burden of influenza-related complications.
- In May 2024, Sanofi and Novavax entered into a co-exclusive licensing arrangement for Novavax’s adjuvanted COVID-19 vaccine. Under the agreement, Sanofi will co-commercialize the vaccine globally, excluding select Asian markets and countries with existing agreements, and obtained rights to develop combination products integrating Novavax’s COVID-19 vaccine with Sanofi’s influenza vaccines, alongside access to the Matrix-M adjuvant technology.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- Vaccine Type
- Formulation
- Patient Group
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape – CSL Ltd. (Seqirus), GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi, among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Flu Shots Market Report Segment
By Vaccine Type
- Inactivated Influenza Vaccines (IIV)
- Recombinant Influenza Vaccines
By Formulation
- Trivalent Flu Shots
- Quadrivalent Flu Shots
By Patient Group
Global Flu Shots Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/flu-shots-market